Approval recommended for Puma Biotechnology's neratinib

The Food and Drug Administration's Oncologic Drugs Advisory Committee recommended approval of Puma Biotechnology Inc.'s (Nasdaq: PBYI) breast cancer treatment neratinib. Shares of the biopharmaceutical leaped $17.15 to close at $74.95



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.